Edema News and Research

RSS
Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.
PPI announces new Exotec Cubital Tunnel Splint

PPI announces new Exotec Cubital Tunnel Splint

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

VERTICAL Phase II trial results for NHL released

VERTICAL Phase II trial results for NHL released

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

CSL Behring selects BioRx as an approved Berinert provider

CSL Behring selects BioRx as an approved Berinert provider

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

Amgen announces results from first Phase 1/2 study of Nplate

Amgen announces results from first Phase 1/2 study of Nplate

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

VELCADE based regimens are cost-effective for payers and patients, finds study

VELCADE based regimens are cost-effective for payers and patients, finds study

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen announces results from three studies on the safety and efficacy of Nplate

Positive final data from Phase 2 study of ISTODAX presented

Positive final data from Phase 2 study of ISTODAX presented

PharmAthene's Valortim demonstrates potential for anthrax treatment

PharmAthene's Valortim demonstrates potential for anthrax treatment

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology